BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › HER2-enriched tumor initiating cell (HTIC) genomic predictor of response following neoadjuvant trastuzumab-based chemotherapy in HER2+...

Dataset: HER2-enriched tumor initiating cell (HTIC) genomic predictor of response following neoadjuvant trastuzumab-based chemotherapy in HER2+ breast cancer

We identified a 17-gene Her2-enriched tumor initiating cell (HTIC) signature in MMTV-Her2/Neu mouse mammary TICs. Here, we show that...

Registered by ArrayExpress Uploader
View Dataset

We identified a 17-gene Her2-enriched tumor initiating cell (HTIC) signature in MMTV-Her2/Neu mouse mammary TICs. Here, we show that patients with HTICS+ HER2+:ERα− tumors are more likely to achieve a pathologic complete response to trastuzumab-based neoadjuvant chemotherapy compared with HER2+:ER+ tumors. Neoadjuvant study of 50 HER2-positive breast cancer cases treated with trastuzumab-based chemotherapy pre-operatively. Pre-treatment FNA from primary tumors were obtained and RNA extracted and hybridized to Affymetrix microarrays according to manufacturer protocol. Pathologic response was assessed at the end of neoadjuvant treatment.

Species:
human

Samples:
50

Source:
E-GEOD-37946

Updated:
Dec.12, 2014

Registered:
Jun.18, 2014


Factors: (via ArrayExpress)
Sample PR AGE STAGE RESPONSE ER
GSM930574 NEG 49 IV RD NEG
GSM930573 POS 62 IIIC RD POS
GSM930572 POS 24 IIIC RD POS
GSM93057 NEG 54 IIIC RD NEG
GSM930570 POS 72 IIB RD POS
GSM930569 NEG 55 IIIC RD NEG
GSM930568 NEG 61 IIIC RD NEG
GSM930567 POS 48 IIIA RD POS
GSM930566 NEG 39 IIIC RD NEG
GSM930565 NEG 50 IIIA RD POS
GSM930564 NEG 44 IIA RD NEG
GSM930563 NEG 51 IIB RD NEG
GSM930562 NEG 61 IIB RD POS
GSM93056 NEG 30 IIIB RD NEG
GSM930560 NEG 52 IIIA RD NEG
GSM930559 NEG 69 IIA RD NEG
GSM930558 NEG 56 IIIC RD POS
GSM930557 NEG 73 IIA RD NEG
GSM930556 POS 47 IIIC RD POS
GSM930555 NEG 41 IIIC RD NEG
GSM930554 POS 49 IIA RD POS
GSM930553 POS 28 IIIB RD POS
GSM930552 NEG 57 IIA RD NEG
GSM93055 NEG 46 IIIC PCR NEG
GSM930550 POS 30 not specified PCR POS
GSM930549 NEG 65 IIB PCR NEG
GSM930548 POS 52 IIIB PCR POS
GSM930547 NEG 56 IIB PCR NEG
GSM93055 NEG 46 IIIC PCR NEG
GSM930545 POS 56 IIIA PCR POS
GSM930544 NEG 53 IIB PCR NEG
GSM930543 NEG 62 IIIC PCR NEG
GSM930542 NEG 55 IIA PCR NEG
GSM93054 NEG 51 IIIB PCR NEG
GSM930540 POS 53 IIIA PCR POS
GSM930539 NEG 41 IIIC PCR NEG
GSM930538 NEG 50 IIIA PCR POS
GSM930537 NEG 63 IIA PCR POS
GSM930536 NEG 38 I PCR POS
GSM930535 NEG 43 IIIA PCR NEG
GSM930534 NEG 51 IIIC PCR NEG
GSM930533 NEG 45 IIIC PCR NEG
GSM930532 POS 56 IIIA PCR NEG
GSM93053 NEG 47 IIA PCR NEG
GSM930530 NEG 36 I PCR NEG
GSM930529 POS 38 IIA PCR POS
GSM930528 NEG 30 IIIA PCR NEG
GSM930527 NEG 52 IIIB PCR NEG
GSM930526 NEG 34 IIA PCR NEG
GSM930525 NEG 50 IIA PCR NEG

Tags

  • breast
  • breast cancer
  • cancer
  • cell

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2026 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use